The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Molecular and histological correlations in liver cancer
Open accessAbstract
Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer, both at the molecular and histological level. High-throughput sequencing and gene expression profiling have identified distinct transcriptomic subclasses and numerous recurrent genetic alterations, and several HCC subtypes characterized by histological features have also been identified. HCC phenotype appears to be closely related to particular gene mutations, tumor subgroups and/or oncogenic pathways. Non-proliferative tumors display a well-differentiated phenotype, and among this molecular subgroup, CTNNB1 mutated HCC constitute a homogeneous subtype with cholestasis and microtrabecular and pseudoglandular architectural patterns. Another non-proliferative subtype has a gene expression pattern close to that of mature hepatocytes (G4) and displays a steatohepatitic phenotype. In contrast, proliferative HCC are most often poorly differentiated, and noticeably include tumors with progenitor features. A novel morphological variant of proliferative HCC, designated as "macrotrabecular-massive", was recently shown to be associated with angiogenesis activation and poor prognosis. Altogether, these findings may help in the near future to translate our knowledge of HCC biology into clinical practice, and are expected to improve precision medicine for patients with this highly aggressive malignancy. This manuscript reviews the most recent data on this exciting field, and discusses the future directions and challenges ahead.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Coudray, N., Ocampo, P. S., Sakellaropoulos, T., Narula, N., Snuderl, M., Fenyö, D., Moreira, A. L., Razavian, N., & Tsirigos, A. (2018) · Nature Medicine · doi:10.1038/s41591-018-0177-5 · Cited by 2,930
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30789-x · Cited by 2,075
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Self-citationZhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453
Self-citationGenetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Self-citationTranscriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Self-citationHoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238
Predicting cancer outcomes from histology and genomics using convolutional networks
Mobadersany, P., Yousefi, S., Amgad, M., Gutman, D. A., Barnholtz-Sloan, J. S., Velázquez Vega, J. E., Brat, D. J., & Cooper, L. A. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717139115 · Cited by 1,084
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Heaphy, C. M., de Wilde, R. F., Jiao, Y., Klein, A. P., Edil, B. H., Shi, C., Bettegowda, C., Rodriguez, F. J., Eberhart, C. G., Hebbar, S., et al. (2011) · Science · doi:10.1126/science.1207313 · Cited by 1,083
Kather, J. N., Krisam, J., Charoentong, P., Luedde, T., Herpel, E., Weis, C.-A., Gaiser, T., Marx, A., Valous, N. A., Ferber, D., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002730 · Cited by 1,082
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J. M., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy308 · Cited by 1,048
Alternative lengthening of telomeres: models, mechanisms and implications
Cesare, A. J., & Reddel, R. R. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2763 · Cited by 1,035
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Yu, K.-H., Zhang, C., Berry, G. J., Altman, R. B., Ré, C., Rubin, D. L., & Snyder, M. (2016) · Nature Communications · doi:10.1038/ncomms12474 · Cited by 972
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Machine Learning Methods for Histopathological Image Analysis
Komura, D., & Ishikawa, S. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.01.001 · Cited by 937
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Totoki, Y., Tatsuno, K., Covington, K. R., Ueda, H., Creighton, C. J., Kato, M., Tsuji, S., Donehower, L. A., Slagle, B. L., Nakamura, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.3126 · Cited by 781
Calderaro, J., Couchy, G., Imbeaud, S., Amaddeo, G., Letouzé, E., Blanc, J.-F., Laurent, C., Hajji, Y., Azoulay, D., Bioulac-Sage, P., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.014 · Cited by 780
Self-citationBiomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Nault, J. C., Mallet, M., Pilati, C., Calderaro, J., Bioulac-Sage, P., Laurent, C., Laurent, A., Cherqui, D., Balabaud, C., & Zucman-Rossi, J. (2013) · Nature Communications · doi:10.1038/ncomms3218 · Cited by 695
Self-citationAdvances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Brown, S. D., Warren, R. L., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 594
β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis
Monga, S. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.056 · Cited by 487
Calderaro, J., Petitprez, F., Becht, E., Laurent, A., Hirsch, T. Z., Rousseau, B., Luciani, A., Amaddeo, G., Derman, J., Charpy, C., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.003 · Cited by 479
Self-citationKurebayashi, Y., Ojima, H., Tsujikawa, H., Kubota, N., Maehara, J., Abe, Y., Kitago, M., Shinoda, M., Kitagawa, Y., & Sakamoto, M. (2018) · Hepatology · doi:10.1002/hep.29904 · Cited by 454
Villanueva, A., Hoshida, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberzon, A., Kobayashi, M., Kumada, H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.006 · Cited by 447
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E., Laurent, A., Azoulay, D., et al. (2016) · Hepatology · doi:10.1002/hep.28710 · Cited by 440
Self-citationDi Tommaso, L., Franchi, G., Park, Y. N., Fiamengo, B., Destro, A., Morenghi, E., Montorsi, M., Torzilli, G., Tommasini, M., Terracciano, L., et al. (2007) · Hepatology · doi:10.1002/hep.21531 · Cited by 427
Durnez, A., Verslype, C., Nevens, F., Fevery, J., Aerts, R., Pirenne, J., Lesaffre, E., Libbrecht, L., Desmet, V, & Roskams, T. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02468.x · Cited by 426
Ahn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424
Self-citationMacSween's Pathology of the Liver
(2012) · Elsevier eBooks · doi:10.1016/c2009-0-47964-9 · Cited by 420
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Kim, H., Choi, G. H., Na, D. C., Ahn, E. Y., Kim, G. I., Lee, J. E., Cho, J. Y., Yoo, J. E., Choi, J. S., & Park, Y. N. (2011) · Hepatology · doi:10.1002/hep.24559 · Cited by 341
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., De Reyniès, A., Villanueva, A., Calderaro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 338
Self-citationPinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Zhang, L., Yang, N., Park, J.-W., Katsaros, D., Fracchioli, S., Cao, G., O’Brien-Jenkins, A., Randall, T. C., Rubin, S. C., & Coukos, G. (2003) · PubMed · Cited by 319
Wei, J. W., Tafe, L. J., Linnik, Y. A., Vaickus, L. J., Tomita, N., & Hassanpour, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-40041-7 · Cited by 306
Histopathology of hepatocellular carcinoma
Schlageter, M., Terracciano, L. M., D’Angelo, S., & Sorrentino, P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.15955 · Cited by 294
Ziol, M., Poté, N., Amaddeo, G., Laurent, A., Nault, J., Oberti, F., Costentin, C., Michalak, S., Bouattour, M., Francoz, C., et al. (2018) · Hepatology · doi:10.1002/hep.29762 · Cited by 249
Self-citationImmunotherapy of Hepatocellular Carcinoma: Facts and Hopes
Iñarrairaegui, M., Melero, I., & Sangro, B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0289 · Cited by 235
Salomao, M., Yu, W. M., Brown, R. S., Emond, J. C., & Lefkowitch, J. H. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181f31caa · Cited by 233
Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R. S., Llovet, J. M., & Bruix, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.261 · Cited by 202
Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy
Wang, B., Tian, T., Kalland, K.-H., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 192
T-cell factor 4 and β-catenin chromatin occupancies pattern zonal liver metabolism in mice
Gougelet, A., Torre, C., Veber, P., Sartor, C., Bachelot, L., Denechaud, P.-D., Godard, C., Moldes, M., Burnol, A.-F., Dubuquoy, C., et al. (2014) · Hepatology · doi:10.1002/hep.26924 · Cited by 190
Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types
Holczbauer, Á., Factor, V. M., Andersen, J. B., Marquardt, J. U., Kleiner, D. E., Raggi, C., Kitade, M., Seo, D., Akita, H., Durkin, M. E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.013 · Cited by 181
Torrecilla, S., Sia, D., Harrington, A. N., Zhang, Z., Cabellos, L., Cornella, H., Moeini, A., Camprecios, G., Leow, W.-Q., Fiel, M. I., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.08.013 · Cited by 181
Salomao, M., Remotti, H., Vaughan, R., Siegel, A. B., Lefkowitch, J. H., & Moreira, R. K. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.07.005 · Cited by 180
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
Fridman, W. H., Dieu‐Nosjean, M., Pagès, F., Cremer, I., Damotte, D., Sautès‐Fridman, C., & Galon, J. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0124-9 · Cited by 178
Moeini, A., Sia, D., Zhang, Z., Camprecios, G., Stueck, A., Dong, H., Montal, R., Torrens, L., Martinez-Quetglas, I., Fiel, M. I., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.010 · Cited by 174
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Kudo, M. (2018) · Cancers · doi:10.3390/cancers10110412 · Cited by 172
Djuric, U., Zadeh, G., Aldape, K., & Diamandis, P. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0022-1 · Cited by 171
Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.121 · Cited by 163
Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162
Yoshida, S., Kornek, M., Ikenaga, N., Schmelzle, M., Masuzaki, R., Csizmadia, E., Wu, Y., Robson, S. C., & Schuppan, D. (2013) · Hepatology · doi:10.1002/hep.26526 · Cited by 162
Kastenhuber, E. R., Lalazar, G., Houlihan, S. L., Tschaharganeh, D. F., Baslan, T., Chen, C.-C., Requena, D., Tian, S., Bosbach, B., Wilkinson, J. E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716483114 · Cited by 160
Ueno, A., Masugi, Y., Yamazaki, K., Komuta, M., Effendi, K., Tanami, Y., Tsujikawa, H., Tanimoto, A., Okuda, S., Itano, O., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.06.008 · Cited by 156
Yang, X., Xu, Y., Shi, G., Fan, J., Zhou, J., Ji, Y., Sun, H., Qiu, S., Yu, B., Gao, Q., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4338 · Cited by 152
Yao, W., He, J., Yang, Y., Wang, J., Qian, Y., Yang, T., & Ji, L. (2017) · Scientific Reports · doi:10.1038/s41598-017-08128-1 · Cited by 152
Seok, J. Y., Na, D. C., Woo, H. G., Roncalli, M. G., Kwon, S. M., Yoo, J. E., Ahn, E. Y., Kim, G. I., Choi, J.-S., Kim, Y. B., et al. (2012) · Hepatology · doi:10.1002/hep.25570 · Cited by 142
Liu, C., Xu, J., Zhou, Z., Jin, L.-L., Yu, X.-J., Xiao, G., Lin, J., Zhuang, S., Zhang, Y., & Zheng, L. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0144-4 · Cited by 122
Engelholm, L. H., Riaz, A., Serra, D., Dagnæs‐Hansen, F., Johansen, J. V., Santoni‐Rugiu, E., Hansen, S. H., Niola, F., & Frödin, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.09.008 · Cited by 114
Zen, C., Zen, Y., Mitry, R. R., Corbeil, D., Karbanová, J., O’Grady, J., Karani, J. B., Kane, P., Heaton, N. D., Portmann, B. C., et al. (2011) · Liver Transplantation · doi:10.1002/lt.22314 · Cited by 109
Clinicopathological indices to predict hepatocellular carcinoma molecular classification
Tan, P. S., Nakagawa, S., Goossens, N., Venkatesh, A., Huang, T., Ward, S. C., Sun, X., Song, W., Koh, A. P., Canasto‐Chibuque, C., et al. (2015) · Liver International · doi:10.1111/liv.12889 · Cited by 104
Lymphoepithelioma-Like Carcinoma in Liver
Labgaa, I., Stueck, A., & Ward, S. C. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.02.022 · Cited by 98
Histopathology of Hepatocellular Carcinoma
Paradis, V. (2012) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-16037-0_2 · Cited by 96
Self-citationWhole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma
Wang, A., Wu, L., Lin, J., Han, L., Bian, J., Wu, Y., Robson, S. C., Xue, L., Ge, Y., Sang, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03276-y · Cited by 96
Wang, Z., Kim, T. B., Peng, B., Karam, J. A., Creighton, C. J., Joon, A. Y., Kawakami, F., Trevisan, P., Jonasch, E. W., Chow, C.-W. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1057 · Cited by 95
Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells
Oikawa, T., Wauthier, E., Dinh, T. A., Selitsky, S. R., Reyna‐Neyra, A., Carpino, G., Levine, R., Cardinale, V., Klimstra, D. S., Gaudio, E., et al. (2015) · Nature Communications · doi:10.1038/ncomms9070 · Cited by 90
Personalized therapy for breast cancer
Abreu, F. B. D., Schwartz, G. N., Wells, W. A., & Tsongalis, G. J. (2014) · Clinical Genetics · doi:10.1111/cge.12381 · Cited by 86
Lymphoepithelioma-like Hepatocellular Carcinoma
Chan, A. W. H., TONG, J. H. M., Pan, Y., Chan, S. L., Wong, G. L., Wong, V. W., Lai, P. B. S., & To, K. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000376 · Cited by 80
Wood, L. D., Heaphy, C. M., Daniel, H. D.-J., Naini, B. V., Lassman, C., Arroyo, M. R., Kamel, I. R., Cosgrove, D., Boitnott, J. K., Meeker, A. K., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.68 · Cited by 80
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
Liao, S., Su, T., Jeng, Y., Liang, P., Chen, D., Chen, C., & Kao, J. (2018) · Hepatology · doi:10.1002/hep.30162 · Cited by 80
Malouf, G. G., Job, S., Paradis, V., Fabrè, M., Brugières, L., Saintigny, P., Vescovo, L., Belghiti, J., Branchereau, S., Faivre, S. J., et al. (2014) · Hepatology · doi:10.1002/hep.27018 · Cited by 75
Self-citationTsuchiya, K., Komuta, M., Yasui, Y., Tamaki, N., Hosokawa, T., Ueda, K., Kuzuya, T., Itakura, J., Nakanishi, H., Takahashi, Y., et al. (2011) · Oncology · doi:10.1159/000328448 · Cited by 74
Liver cancer biopsy – back to the future?!
Torbenson, M. S., & Schirmacher, P. (2014) · Hepatology · doi:10.1002/hep.27545 · Cited by 71
Sarcomatoid renal cell carcinoma: Biology and treatment advances
Mouallem, N. R. E., Smith, S. C., & Paul, A. K. R. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.12.012 · Cited by 71
Rebouissou, S., Bella, T. L., Rekik, S., Imbeaud, S., Calatayud, A.-L., Rohr‐Udilova, N., Martin, Y., Couchy, G., Bioulac‐Sage, P., Grasl‐Kraupp, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3118 · Cited by 67
Self-citationChae, Y. K., Anker, J. F., Bais, P., Namburi, S., Giles, F. J., & Chuang, J. H. (2017) · Oncotarget · doi:10.18632/oncotarget.23742 · Cited by 67
Squiring immunotherapy to CheckMate
Hutchinson, L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.110 · Cited by 63
Lai, J., Conley, A., Knudsen, B. S., & Guindi, M. M. (2014) · Histopathology · doi:10.1111/his.12623 · Cited by 61
Lee, J. S., Yoo, J. E., Kim, H., Rhee, H., Koh, M. J., Nahm, J. H., Choi, J. S., Lee, K.-H., & Park, Y. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171922 · Cited by 53
Ando, S., Shibahara, J., Hayashi, A., & Fukayama, M. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1836-2 · Cited by 50
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer
Song, Z., Cheng, G., Xu, C., Wang, W., Shao, Y. W., & Zhang, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.02.004 · Cited by 50
Patel, K. R., Liu, T., Vaccharajani, N., Chapman, W. C., & Brunt, E. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0371-oa · Cited by 43
Biopsy for liver cancer: How to balance research needs with evidence‐based clinical practice
Sherman, M., & Bruix, J. (2014) · Hepatology · doi:10.1002/hep.27563 · Cited by 43
Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas
Solinas, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i12.3472 · Cited by 42
Kuijer, A., Straver, M. E., den Dekker, B. M., van Bommel, A. C. M., Elias, S. G., Smorenburg, C. H., Wesseling, J., Linn, S. C., Rutgers, E. J. T., Siesling, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3959 · Cited by 41
Lantuéjoul, S., Adam, J., Girard, N., Duruisseaux, M., Mansuet‐Lupo, A., Cazes, A., Rouquette, I., Gibault, L., Garcia, S., Antoine, M., et al. (2018) · Annales de Pathologie · doi:10.1016/j.annpat.2018.01.007 · Cited by 30
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features
Malouf, G. G., Tahara, T., Paradis, V., Fabrè, M., Guettier, C., Yamazaki, J., Long, H., Lu, Y., Raynal, N. J. ‐., Jelı́nek, J., et al. (2015) · Epigenetics · doi:10.1080/15592294.2015.1076955 · Cited by 19
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationPrecision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
WNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 351
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma
Calderaro, J., Seraphin, T. P., Luedde, T., & Simon, T. G. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.014 · Cited by 342
Self-citation
Metadata
- Authors
- Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 71
- Issue
- 3
- Pages
- 616-630
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2952676090
- Cited by
- 590
- References
- 127
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.